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Abstract
The mutually conflicting surface charge requirements for nanoparticles to have long circulation and good cell affinity have made the development of polymer nanoparticles for controlled drug delivery fall into a dilemma. In order to
solve this problem, the first attempt has been made in this work to develop vancomycin loaded composite nanoparticles
with a novel chitosan core and poly (lactide-co-glycolide) (PLGA) shell structure and with both pH-responsive and surface charge switchable properties. Spherical composite nanoparticles have been successfully fabricated through a modified emulsion-gelation method with a controllable size (316–573 nm), surface charge (–27.6–31.75 mV) and encapsulation efficiency up to 70.8%. The dilemma can be avoided by tailoring the composite nanoparticles with the specially
designed core-shell structure to be negative charged in the beginning and switch to positive charge later on. The negative charge of particles can be switched to positive charge gradually as the erosion of biodegradable polymer shells and
exposure of the positive charged chitosan core. The formed chitosan hydrogel exhibited multi-layer structures, which
were primarily influenced by chitosan concentration. Influences of the chitosan gelation behaviors on the properties of
the composite nanoparticles in response to different chitosan and NH3 concentrations have also been studied. Release
rate decreased significantly with increasing chitosan concentration. With the introduction of the chitosan, the increase
in drug release rate by orders of magnitude was observed for the samples immersing in the phosphate buffer saline solution of lower pH value proving a pH responsive release property. Drug release profiles of the composite nanoparticles were divided into fast release stage and slow release stage. The fast release stage was well described by a modified
first-order kinetic model; while the slow release stage was fitted well with the classical first-order release kinetic model.
All the presented results make the proposed composite nanoparticles a promising system for controlled drug delivery.
Keywords: Polymer-matrix composites (PMCs), Nano-structures, Particle-reinforcement, Microstructures, Chitosan,
Surface charge

1. Introduction

with the size and surface properties of nanoparticles [9]. The
internalization process is usually enhanced by grafting targeting ligands or the positive charged surfaces of nanoparticles, since these decorations on the particle surfaces can
induce the ligand-receptor interactions or electrostatic interactions with cell membranes [10]. It has been discovered
that positive charged or ligand decorated nanoparticles are
generally easy to be recognized and cleared by the reticuloendothelial system (RES), which can significantly reduce
the circulation time and thus deteriorate the accumulation
of nanoparticles on tumor sites [11]. Prolonged circulation
time and enhanced accumulation can be achieved by adopting
negatively charged nanoparticles modified with hydrophilic

Polymer nanoparticles with targeting capability have been
widely developed as promising drug delivery vehicles [1–3].
Enhanced disease tissue accumulation and cellar internalization are two basic properties for nanoparticles to have
achieved target delivery [4–6]. Tumor accumulation is usually achieved through a long circulation time and the permeability and retention (EPR) effect, which allows nanoparticles
to penetrate through the leaky tumor vasculature other than
normal tissue in a passive way [7,8]. Cellular internalization
is another important step for the accumulated nanoparticles
to have efficacious therapeutic results, which is associated

83

84
groups, such as PEG, on their surfaces [12]. However, the negative charge and hydrophilic groups could hinder the interactions between nanoparticles and cell membrane, which is
unfavorable for cellular interaction [13].
In order to solve this dilemma, nanoparticles with switchable surface properties are desirable. Nanoparticles are required to exhibit a negative charge before reaching tumor
sites. After their accumulation on the tumor tissues, the
nanoparticles are required to become positively charged in
order to accelerate the cellular internalization. To realize this
delivery strategy, some attempts have been employed to develop surface charge-switchable nanoparticles [7]. Hung et
al. [14] developed a pH-triggered surface charge-switchable
poly (lactide-co-glycolide) (PLGA) nanoparticles for drug delivery by grafting pH-responsive N-acetyl histidine modified d-αtocopheryl polyethylene glycol succinate chains on the surface
of the PLGA nanoparticles. These modified PLGA nanoparticles
changed to be positively charged after being triggered by acid
tumor extracellular environment due to the enhanced protonation of the grafted functional groups. In another study, negatively charged 2, 3-dimethylmaleic anhydride (DMMA) groups
were introduced to shield the positively charged nanoparticles
by binding them with the amino groups on the particle surfaces [15]. The DMMA groups detached from the amino groups
responding to the tumor extracellular acidity would recover to
become positively charged. Another strategy to achieve surface charge switching is the adoption of the Zwitterionic surfaces [16–18]. A variety of pH-responsive zwitterionic groups
have been developed for the surface modification of nanoparticles, such as carboxybetaine [16], phosphorylcholine [17] and
alkoxyphenyl acylsulfonaminde [18]. These functional groups
are capable to switch from negative or neutral charges to positive charges at acidic environments. Thus, this type of surface
modification has been proved to be an effective route to equip
nanoparticles with a surface charge switching property. However, these surface modification processes are usually complex and may deteriorate the nanoparticles in certain extend.
PLGA, an American food and drug administration (FDA)
approved polymer, has attracted increasing attentions as the
primary composition of nanoparticles for drug delivery purpose, because of its degradability and controllable drug release profile [1,8,19–21]. However, the negatively charged surfaces of PLGA based nanoparticles render them inappropriate
to have effective targeting effects. Chitosan, a natural occurring biodegradable polymer acquired from the deacetylation
of chitin, has been widely adopted in industrial and pharmaceutical applications, because of its intrinsic properties such
as biocompatibility, biodegradability, bacteriostatic effect and
abundance in nature [1,22–25]. The positive charges of chitosan based nanoparticles are beneficial for cell affinity and internalization. However, the circulation time is compromised.
In this study, with motivation by the merits of both polymers, we have designed a novel and facile strategy for fabricating effective pH-responsive and switchable surface charged
chitosan hydrogel/PLGA core-shell composite nanoparticles for
drug delivery. A model drug, vancomycin HCl, was incorporated into the pH-responsive chitosan hydrogel core which was
then encapsulated by the PLGA shell through a one-step emulsion gelation method. With the developed core-shell structure,
the positively charged chitosan could be physically shielded.
Following the erosion of the polymer shell and the exposure of chitosan core, the surface properties of the composite
nanoparticles were switched from negative to positive charges.
Gelation behaviors of the chitosan solution in response to the
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concentration of chitosan and alkali were studied. Influences
of key fabrication parameters on the particle size, drug encapsulation efficiency, surface charge and drug release kinetics of
the composite nanoparticles were all investigated.
2. Material and methods
2.1. Materials
Poly (lactic-co-glycolic acid) (PLGA) (Mw: ~30 kDa) and Poly
((D, l-lactic acid-co-glycolic acid)-block-ethylene glycol)
(PLGA-PEG) (Mw: ~11 kDa) were obtained from the Jinan Daigang Biomaterial Co., Ltd. Dichloromethane (DCM), acetate
acid and NH3 solution were purchased from the Merck & Co.
Polyvinyl alcohol (Mw: ~23 kDa) and tetraethylorthosilicate
(TEOS) were acquired from the Sigma-Aldrich. Vancomycin
HCl (VCM) was obtained from the Amresco. Chitosan (Mw =
~500 kDa, deacetylation degree, > 95%) was purchased from
the Heifei Bomei Biotechnology Co., Ltd.
2.2. Fabrication of drug loaded chitosan/PLGA composite
nanoparticles
The proposed composite nanoparticles were prepared through
a modified gelation emulsion method [26]. Briefly, 30 mg of
VCM was dissolved into 1 ml of chitosan solution. Chitosan solutions of different concentration (0.5%–2%) were prepared
by dissolving the chitosan powder into acetate acid aqueous
solution of the same concentration. 1 ml of the chitosan-VCM
solution and 0.1 ml of NH3 solution were ultrasonically emulsified into 5 ml of PLGA/DCM solution separately to form two
emulsions. The PLGA/DCM solution was prepared by dissolving PLGA and PEG-PLGA with a weight ratio of 3: 2 into 5 ml
of DCM. Both of the emulsions were blended and sonicated for
3 min to give a primary emulsion. The primary emulsion was
then ultrasonically dispersed into 22 mL of 0.5% PVA solution
to form the secondary emulsion which was then agitated for
3 h to evaporate all the organic solvent. The nanoparticle suspension was centrifuged at 12000 rpm for 30 min. The supernatants were kept for drug concentration analysis. The composite nanoparticles were obtained after washing and drying
the precipitated solids.
2.3. Characterization
The morphologies and structures of the composite nanoparticles were examined using scanning electron microscopy (SEM)
(JEOL JSM-6490) and STEM (JEOL JEM-2100F). Specimens for
SEM were treated by coating a gold layer. Compositional information on the nanoparticles was obtained by Fourier Transform Infrared (FTIR) spectrometry (Thermo Scientific Nicolet
IS50). The size and zeta potential of the nanoparticles were
measured by a Zetasizer Nano ZS (Malvern Instruments, Malvern, U.K.) instrument.
2.4. Determination of encapsulation efficiency
The concentration of VCM in the supernatant was identified
by measuring its absorbance using the UV spectrophotometry
at 280.5 nm. A standard curve, that was used to calibrate the
relationship between the drug concentration and UV absorbance, was prepared using a drug concentration of 0.6–0.032
mg/ml in 0.5% of PVA. The standard curve of drug concentration in response to UV absorbance was determined to be y

C o m p o s i t e n a n o pa r t i c l e s f o r d r u g d e l i v e ry a p p l i c at i o n
= 0.16672x – 0.00421 with a correlation factor R2 of 0.999 in
regression analysis. The encapsulation efficiency (EE) of the
vancomycin in the nanoparticles was determined by identifying the concentration of the nonencapsulated free drug in
the supernatant after centrifugation of the nanoparticle suspension at 12000 rpm for 30 min. The EE of the drug loaded
nanoparticles was calculated by using the following equation:
Encapsulation Efficiency (%)
=

Total drug amount – Free drug amount
Total drug amount

× 100%

2.5. In vitro drug release
An appropriate amount of nanoparticles containing 3 mg of
VCM were dispersed into 40 ml of phosphate buffer solution
(PBS) (pH = 7.2 ± 0.2) in a 50 ml tube with a cap. The tube
was shaken at 100 cycles/min in a gas bath shaker with a constant temperature of 37.0 ± 0.2 °C 4 ml of dissolution medium
was withdrawn from each tube at a fixed time interval. After centrifugation at 12000 rpm for 10 min, 2 ml of supernatants of the collected dissolution medium samples were filtered through 0.22 μm-membrane before analyzing the drug
concentration via UV/vis spectrophotometry at 280.5 nm. All
the dissolution mediums were added back to the corresponding tube after the completion of analysis.
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the particle size increases from 404 to 573 nm with decreasing chitosan concentration from 2% to 0.063% for a constant
ratio of chitosan to NH3 concentration. It can also be observed
from Fig. 2 that the particle size and surface charge (zeta potential) of the composite nanoparticles rise with the NH3 concentration before 3% NH3 concentration. The particle size exhibits only a mild decrease when the NH3 concentration is
above 6%, which is due to the formation of more compact hydrogel in the presence of the extra alkali. With different chitosan and NH3 concentrations, encapsulation efficiency (EE)
and Zeta potential also vary from 56.1% to 70.8% and –27.6–
31.75 mV respectively (Figs. 2 and 3). All these results are further discussed in the following sections.
3.2. FT-IR analysis
The comparative FI-IR spectrum of PLGA, chitosan, PEG-PLGA
and composite nanoparticles is presented in Fig. 4. The strong
peak at 1755 cm–1 is assigned to the stretching vibration of the
ester C=O of PLGA and PEG-PLGA. The asymmetric and symmetric stretching vibration of the C-H bonds of –CH3 groups
of the PLGA and PEG-PLGA are characterized by the peaks at

3. Results and discussion
3.1. Size, morphology, encapsulation efficiency and zeta potential of the composite nanoparticles
Composite nanoparticles prepared with 1% of chitosan and
1.5% NH3 concentration in this study were spherical as confirmed in the SEM image in Fig. 1(a), and their particle size
distribution was acceptable with a low polydispersity index
of 0.262. For the composite nanoparticles prepared with 1%
of chitosan concentration, their size increases up to 413 nm
with increasing NH3 concentration from 0.75% to 3%, while
there is a decrease in the particle size up to 367 nm for the
NH3 concentration of 3%–12% as shown in Fig. 2. From Fig. 3,

Fig. 2. Comparison of composite nanoparticles prepared with different NH3 concentration and a constant 1% chitosan concentration.

Fig. 1. Composite nanoparticles prepared with 1% of chitosan and 1.5% NH3 concentration (Average diameter: 334 nm, Polydispersity index: 0.262), (a) SEM image, and (b) particle size distribution.
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Fig. 3. Comparison of composite nanoparticle prepared with different chitosan concentration at a constant ratio (1:3) of chitosan
to NH3 concentration.

3003 cm–1 and 2955 cm–1 respectively. The peak at 2883 cm–1 is
due to the C–H stretching vibration of –CH2. The characteristic
peaks at 1645 cm–1 and 1598 cm–1 are the N-H bending vibration
of the primary and secondary amides of chitosan respectively,
confirming the presence of chitosan in the composite nanoparticles. The stretching vibrations of N–H and O–H groups of chitosan are expressed as the wide and sharp peak at 3480 cm–1 in
Fig. 4 (d). The peaks at ~3480 cm–1 of the PLGA and PEG-PLGA
are associated with the –OH stretching vibration.
3.3. Investigation on gelation process of chitosan solution
The chitosan solution in this study was physically gelled by
the exposure to alkali, leading to the entanglement of the chitosan molecular chains. Referring to our fabrication process,
the chitosan solution and NH3 solution were firstly dispersed
into the individual PLGA/DCM solution. The gelation of the
chitosan solution droplets was triggered by their collisions
with the droplets of NH3 solution. The collisions may occur
between two different droplets or among multiple droplets
as confirmed in TEM image (Fig. 5 (a) & (b)). After collision,
the NH3 solution droplets start to merge with the chitosan
solution as shown in Fig. 5(c). According to Fick’s first law,
the solute (NH3) diffused from a high concentration region
(NH3 droplet) to a low concentration region (chitosan droplet) across a concentration gradient.
This gradient diffusion of the alkali solution has been found
to enable formation of multilayer chitosan hydrogel instead of
forming cross-linked gel simultaneously as reported in literature [27]. According to their study, the gelation speed of the
chitosan solution decreased while the alkali solution diffused
from the top to the bottom, leading to formation of multilayer
chitosan hydrogel with different structure. A primary chitosan hydrogel layer with a smooth and compact structure was
formed promptly on the interface once in contact with the alkali solution. Following the continuous diffusion of alkali solution to the bottom, an oriented layer, which is characterized
by a diffusion direction oriented structure with minor porosity, was formed. In this layer, some of the chitosan molecular
chains was deprotonated and embed in the upper unit, while
the other part of the chains were relaxed and able to interact with other unrestricted protonated molecular chains. Due
to the diffusion of the alkali solution, the relaxed part of the
molecular chains was restricted and the chitosan molecular
chains interacting with this part of the chains was therefore
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Fig. 4. FT-IR spectra of (a) PEG-PLGA, (b) PLGA, (c) composite
nanoparticle and (d) chitosan.

aligned. This orientation has been found to occur only in the
high chitosan concentration. It was also found that there was
a critical chitosan concentration below which the orientation
layer could not be formed. The viscosity of the chitosan solution for its concentration above and below the critical values was found to vary significantly. This critical chitosan concentration was found to be reduced with increasing molecular
weight of the chitosan. A highly porous layer was formed in
the highly reduced alkali solution or in the chitosan solution
with the concentration below its critical value, which was considered to be isotropic.
In the current study, the alkali (NH3) droplet diffused from
its center towards outward. The generated chitosan hydrogel core was assumed to have a multi-layer structure following the similar gelation process as discussed above. As illustrated in Fig. 6, there should be a compact, oriented and
porous structure and unreacted chitosan along the diffusion
direction of the NH3 droplets. Thus, the gelation behaviors
of the chitosan solution and the properties of the composite
nanoparticles became highly dependent on the concentration
of the chitosan and NH3 solutions.
3.4. Control and influences of the gelation behavior of
chitosan
The critical polymer concentration has been discovered to be
0.56 wt% for the chitosan of molecular weight of 200 kDa
as reported in literature [27]. Since the molecular weight of
the chitosan in the present study is about 500 kDa, the critical concentration should be lower than 0.56 wt%. A series of
the chitosan concentrations ranging from 0.0625 to 2.0 wt%
were therefore adopted to determine its critical concentration,
and explore the properties changes of the composite nanoparticles around this critical concentration. From Fig. 3, the critical chitosan concentration was found to be 0.37 wt%, as reflected from the most remarkable change of the particle size
over other properties. It can also be observed from this figure
that the particle size exhibits an insignificant decrease with
increasing chitosan concentration above the critical value, but
increases significantly for the chitosan concentration below
the critical value. As discussed in Section 3.3, most of the chitosan gel had a highly porous structure, because the oriented
layer was rarely formed when the chitosan solution was below the critical value. Moreover, this porous structure could
encapsulate and prevent the outflow of more water molecules
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Fig. 5. Images and schematic formation of chitosan hydrogel core during fabrication, (a) & (b): TEM images of composite nanoparticles.
(c) Schematic integration and diffusion of NH3 into chitosan droplets.

Fig. 6. Schematic chitosan core structure.

as well as drug molecules as compared with the less porous
oriented layer. This result has been confirmed by the increasing tendency of EE with the decrease of chitosan concentration, especially when the concentration is below the critical
value (Fig. 3). Surface properties of the composite nanoparticles, in terms of surface charge, exhibited a proportional relationship with the chitosan concentration, which is primarily
ascribed to the reducing content of positively charged chitosan in the nanoparticles. It was because the surface charge of
the nanoparticles changed from a negative to positive one due
to the introduction of the chitosan as the core material. This
charge change may result from partially protonated chitosan
molecular chains tending to penetrate through the polymer
shell and influence the charge balance of the particles; while
the deprotonated part of the chitosan chains was embedded
in the hydrogel matrix of the particle core. The amount of the
added alkali (NH3) solution was just enough to neutralize acetate acid in each formulation of the samples in Fig. 3. The
protonated chitosan molecules at the surface of hydrogel core
were supposed to be deprotonated by the addition of extra alkali, which could therefore change the charge of the particles.
To verify this assumption, different NH3 concentrations were
adopted for preparation of composite nanoparticles containing 1% chitosan solution.

Referring to the results depicted in Fig. 2 and described in
section 3.1, 3%NH3 concentration was just enough to cause
gelation of the nanoparticles by neutralizing all the acid in
the 1% chitosan concentration. It was because the chitosan
solution could not be gelled or deprotonated completely when
the NH3 concentration is below 3%). The unrestricted protonated (unreacted) chitosan molecules tended to escape from
the nanoparticles under sonication during fabrication process,
leading to the reduction of particle size with decreasing NH3
concentration. The surface charge of the composite nanoparticles switched from a positive to a negative charge one as in
Fig. 2 when the extra NH3 (with concentration > 3%) was introduced. This result confirmed the previous assumption that
the protonated part of the chitosan could be deprotonated and
restricted when the extra alkali was used. From Fig. 2, a further increase of the NH3 concentration (>3%) would lead to
formation of less unrestricted and protonated chitosan molecular chains. The impact of the positively charged chitosan
on the negatively charged polymer shell was therefore minimized. Zeta potential of composite nanoparticles decreases
slightly in a lower NH3 concentration (<3%) as in Fig. 2 owing to the leakage of the protonated and free chitosan molecules during fabrication. The composite nanoparticles with a
negative charge can be switched to possess a positive charge,
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Fig. 7. Drug release profiles of composite nanoparticles with various chitosan concentrations under different stages. (a) the entire drug release stage, (b) the fast release stage (≤24 h), and (c) the slow release stage (>24 h).

when the cores of the drug loaded chitosan were exposed to
the body fluid after erosion of its polymeric shells. This equips
the nanoparticles with advantageous properties of both long
circulation time and good cell affinity.
3.5. In vitro drug release kinetic
Drug release profiles of composite nanoparticles prepared
with chitosan concentrations ranging from 0.25% to 2% are
presented in Fig. 7. Drug releases within 24 h and 2 weeks
vary from 83% to 48% and 95%–68% respectively with increasing chitosan concentration up to 2%. Because of the coreshell structure of the composite nanoparticles, the drug molecules released from the chitosan core were influenced by the
erosion of polymeric shells, degradation of the chitosan, dissolution and diffusion of the drug molecules. The drug release
profiles of the composite nanoparticles were approximated by
two stages: an initial fast release stage within the first 24 h
and a subsequent sustained slow release stage. The first release stage resulted from a combinational effect of dissolution
and diffusion of the drug molecules that were embedded in the
polymeric shell and entrapped in the porous layer of the chitosan core. The release profiles of the first stage release reflected the diffusion controlled dissolution of the embedded
drugs. After most of the drug molecules embedded in polymeric shell and the porous structure of the chitosan hydrogel
core were released within the first 24 h, the release rate of the
entire system became reduced significantly. According to the
characteristics of the fast release stage, the cumulative release

at any time during the first 24 h could be approximated to be
the upper limit (A) of the fast release stage. This release behavior could be characterized by the following equation developed based on the first-order kinetics [28] modified with
an additional upper limit, A.
Mt

M∞

= A (1 – e –kt )

(1)

where Mt and M∞ are defined as fractions of the released
drugs at time t and infinite time respectively; k is the release
rate constant. This modified first order kinetic would become
classic first-order kinetic when A is equal to 1. Therefore,
equation (1) is applied to characterize the situations when A
is not equal to 1.
Regression analysis of the data was performed using equation (1) and the results are shown in Table 1. The release rate
constant (k) increases gradually with reducing chitosan concentration, especially when the concentration is lower than
0.5% (Fig. 8). This result is coincident with the relationship
between the chitosan concentration and formation of the porous layer as described in Section 3.3. Comparison between
the predicted and experimental values of A is presented in Table 1 and Fig. 9. The relative errors of between predicted and
experimental A values were found to be smaller than 7%, with
no significant difference as confirmed in a student t-test with
p < 0.05. All these analysis results have confirmed the effectiveness of equation (1) in describing the drug release kinetics of the composite nanoparticles in the fast release stage.
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Table 1. Correlation coefficient (R), release rate constant and release upper limit of the modified kinetic model (As1) for first release stage.
Parameter

2.00%

1.00%

0.50%

0.25%

Correlation coefficient (R)
K
Predicted A
Experimental A

0.998
0.145 (±0.0078)
50.57%
48%

0.996
0.144 (±0.014)
71.39%
67%

0.999
0.220 (±0.0085)
72.12%
72%

0.999
0.360 (±0.020)
81.33%
83%

Table 2. Correlation coefficient (R) of different release kinetic
models for the slow release stage.
Model

2.00%

1.00% 0.50%

0.25%

Zero order
Classical First Order (A = 1)
Higuchi

0.897
0.913
0.906

0.985
0.989
0.987

0.975
0.995
0.978

0.974
0.980
0.976

dominating effects, because the drug molecules encapsulated
in the chitosan cores, before releasing to the external PBS,
were required to penetrate through the eroded polymer shell
and chitosan matrices. To investigate this combinational effect, several release kinetics were investigated. Drug release
from biodegradable PLGA are usually characterized by the
classical first-order kinetics considering the hydrolytic degradation behaviors of polymers [28], which can be expressed
by equation (1) with A = 1.
Drug released from chitosan nanoparticle was found to be
best fitted with the Higuchi square root of time model [29,30]:

( )
Mt
M∞

2

= kt

(2)

As shown in Fig. 7(c), the release profiles exhibit a linear
relationship, which is usually described by the zero order
release kinetics [31]:
Mt
= kt
M∞

Fig. 8. Release rate constants (k) for the first release stage with different chitosan concentrations (pH = 7.4).

Fig. 9. Comparison of predicted and experimental release upper
limit (A) values.

The following slow release stage may be ascribed to the
combinational effects of the erosion of polymer shells, erosion of chitosan matrices, dissolution and diffusion of the drug
molecules encapsulated in the oriented and compact structures of the chitosan hydrogel cores. Erosion of the polymer shells and chitosan matrices were assumed to be the

(3)

To evaluate the effectiveness of these models, regression
analysis was performed by fitting the data by various the kinetics models. Correlation coefficients (R) of the aforesaid
models are compared in Table 2. The first order kinetics show
the best fit with the cumulative release data for the slow release stage. From Fig. 10, the release rate constant (k) at
0.25% chitosan concentration is 5 times greater than that of
higher chitosan concentration due to the absence of the oriented structure in the chitosan with a concentration lower
than its critical value of 0.37%.
Influences of external stimuli, in terms of pH value, on
drug release profiles of the drug loaded composite nanoparticles were evaluated by immersing the samples in PBS solution with different pH values. As shown in Fig. 11, a significant
increase for the drug release rate of the nanoparticles is observed for the samples in the PBS solution of lower pH value.
The samples in the PBS solution of pH = 1.2 exhibits the fastest release rate and realize 100% release in 5 days; but the
sample in the PBS solution of pH = 4.8 shows a complete release in 14 days. Regression analyses of the fast release stage
and slow release stage were performed by using the modified
first-order kinetic (As1) and the classical first-order kinetic
(A = 1) equations, respectively (Table 3). For the fast release
stage, a relatively mild increase in the release rate with reducing pH values is observed, because the erosion of polymeric
shell in this stage was relatively less impacted by the pH value
of PBS solution. For the slow release stage, the increase in the
release rate becomes more significant as shown in Fig. 11(c),
because the primary effect of the second stage release is the
swelling and degradation behavior of the chitosan which is
significantly influenced by the pH value. As the chitosan molecular chains were protonated in a lower pH solution, it led
to the swelling and dissolution behaviors, and contributed to
the fast release rate of the encapsulated drugs.
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Table 3. Regression results of samples in PBS solutions with different pH values.
Parameter

pH = 7.4

pH = 4.8

pH = 1.2

Fast release stage
K
Slow release stage
K (10–4)

0.996
0.144 (±0.014)
0.989
6.07 (±0.46)

0.981
0.157 (±0.030)
0.989
66.5 (±5.62)

0.985
0.207 (±0.034)
1
233.2

Fig. 10. Release rate constants (k) for the slow release stage with
different chitosan concentrations (pH = 7.4).

4. Conclusion
Surface charge switchable and pH responsive vancomycin
loaded chitosan/polymer composite nanoparticles of a novel
core-shell structure with an adjustable size range of 316–573
nm and a drug encapsulation efficiency up to 70.8% have been
successfully fabricated in the first attempt via a modified gelation emulsion method. Surface charges of the particles could
be controlled from –27.6–31.75 mV by adjusting the concentrations of the chitosan and NH3 solutions. The conflicts of
long circulation time and good cell affinity could be avoided
by developing negatively charged composite nanoparticles, because the exposure of the chitosan core after degradation of
the polymer shells could switch the nanoparticles to possess
a positive charge. The generated chitosan hydrogel core exhibited multi-layer structures with a combination of compact
layer, oriented layer and highly porous layer along the diffusion direction of the incorporated NH3 solution, which have
been found to influence the properties of composite nanoparticles. Formation of multilayer chitosan hydrogel was found to
be related to the concentration of chitosan solution. The critical chitosan concentration was confirmed to be 0.37%, below which no oriented structure was formed. Moreover, influences of the gelation behaviors of chitosan solution on the
size, zeta potential, encapsulation efficiency as well as drug
release were well investigated. Drug release profiles of the
nanoparticles were classified into a fast release stage (≤24
h) and a slow release stage (>24 h). The fast release stage
was caused by the diffusion controlled dissolution behaviors

Fig. 11. Drug release profiles of composite nanoparticles with 1% chitosan concentrations in PBS of different pH values under different
stages. (a) the entire drug release stage, (b) the fast release stage (≤24 h), and (c) the slow release stage (>24 h).

C o m p o s i t e n a n o pa r t i c l e s f o r d r u g d e l i v e ry a p p l i c at i o n
of drug molecules embedded in the polymeric shell and the
porous structure of the chitosan core, which exhibited modified first-order release kinetics. The slow release stage was
attributed to the erosion of polymer shells and chitosan cores
of the nanoparticles, which was found to follow the classical first-order release kinetics. In addition, the release rates
(slow release stage) of the composite nanoparticles were accelerated by two orders of magnitude in a PBS solution with
a pH value reduced from 7.4 to 1.2, which confirmed the pHresponse functions of the proposed composite nanoparticles
that are applicable for effective treatment of the disease cells/
tissues with an acid cellular environment.
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